Drug
Iodine-123 clinical trials
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
18 studies that test it; most in 2007 (6)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2003 | 1 |
| 2006 | 5 |
| 2007 | 6 |
| 2013 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 16
Institute for Neurodegenerative Disorders (12) · Molecular NeuroImaging (3) · GE Healthcare (2) · Tomsk National Research Medical Center of the Russian Academy of Sciences (1)
Studies
Open first, then newest update. How each study uses Iodine-123 is read from its arms, and is right about nine times in ten.
Testing it · 18
- Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1CompletedPhase 1Tomsk National Research Medical Center of the Russian Academy of SciencesNCT06386653Written as Diagnostic injection of [123I]I-DARPIN-Ec1
- A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese PatientsCompletedPhase 3GE HealthcareNCT04193527Written as DaTSCAN™ Ioflupane (123I) Injection
- A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers.CompletedPhase 1GE HealthcareNCT04564092Written as DaTSCAN™ Ioflupane (123I) Injection
- A Study Evaluating Potential Screening Tools for Detecting Parkinson DiseaseStatus unknownPhase 2Institute for Neurodegenerative DisordersNCT00387075Written as [123I]β-CIT
- Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy SubjectsCompletedPhase 1Institute for Neurodegenerative DisordersNCT00556660Written as [123I] AV-151
- Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.CompletedPhase 1Molecular NeuroImagingNCT01859767Written as [123I]MNI-672 SPECT
- Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease ProgressionCompletedPhase 2Institute for Neurodegenerative DisordersNCT00134784Written as [123I]B-CIT SPECT imaging
- Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic UncertaintyCompletedPhase 2Institute for Neurodegenerative DisordersNCT00129675Written as [123I]ß CIT
- Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's DiseaseCompletedPhase 2Institute for Neurodegenerative DisordersNCT00315250Written as [123I]β-CIT
- Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk FamiliesCompletedPhase 2Institute for Neurodegenerative DisordersNCT00273351Written as [123I]B-CIT
- Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer DiseaseCompletedPhase 2Institute for Neurodegenerative DisordersNCT00480701Written as [123I]-IBVM
- Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons DiseaseCompletedPhase 2Institute for Neurodegenerative DisordersNCT00397696Written as [123I] 5-IA
- A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's DiseaseCompletedPhase 2Institute for Neurodegenerative DisordersNCT00117819Written as [123I]ß CIT and SPECT imaging
- Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the BrainCompletedPhase 1Institute for Neurodegenerative DisordersNCT00287248Written as [123I] IMPY & SPECT Imaging
- Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease PatientsTerminatedPhase 1Institute for Neurodegenerative DisordersNCT00427674Written as [123I] mZINT injection and serial dynamic SPECT imaging
- Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy SubjectsTerminatedPhase 1Institute for Neurodegenerative DisordersNCT00605059Written as [123I]AV94
- Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HCTerminatedPhase 1Molecular NeuroImagingNCT00544453Written as [123I] MNI-308
- Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy SubjectsCompletedPhase 1Molecular NeuroImagingNCT00439010Written as [123I] AV 39
Codes
What other systems call Iodine-123 · ClinicalTrials.gg INT000618
- MeSH (NLM) C000614958Iodine-123One source NLM
- UNII (FDA) 8YWR746RPQIODINE I-123Confirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000614958 | Iodine-123 | One source NLM |
| UNII (FDA) | 8YWR746RPQ | IODINE I-123 | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.